A team of researchers affiliated with Johns Hopkins University and Memorial Sloan Kettering Cancer Center has found some of the reasons for different responses to anti-PD-1 checkpoint blockade immunotherapy in cancer patients. ...
A team of researchers with member affiliations across the U.S. and Canada has found evidence of multiple recurrent, repeat expansions in human cancer genomes. In their paper published in the journal Nature, the group describes ...
The referenced article describes an assay that has a clinically relevant five-day turnaround time and can be conducted on as little as 20 ng genomic DNA with a batch size of up to forty samples in a single run.
Oct 18, 2019
0
16
Cancer cells adapt to potentially fatal mutations and other molecular malfunctions by adjusting one or more other genes' activity, in the process becoming dependent on those genes for their survival and growth. The resulting ...
Apr 11, 2019
0
100
The immense progress in the field of therapy options over the past years has significantly improved the chances of cure for patients with colon cancer. However, these new approaches, such as immunotherapies, require precise ...
Feb 14, 2023
0
41
Results of a study led by VHIO investigators and published in Nature Medicine have unmasked mutations in the RNF43 gene as predictive biomarkers of response to treatment with anti-BRAF/EGFR combinatory therapy in patients ...
Sep 27, 2022
0
35
A large international trial involving UCL and University College London Hospitals NHS Foundation Trust (UCLH) has found that pembrolizumab, a form of immunotherapy, more than doubled the 'progression free survival' time of ...
May 29, 2020
0
3
Foundational research by a City of Hope physician-scientist and his colleagues could one day help metastatic colorectal cancer patients decide whether to choose immunotherapy or chemotherapy as their first treatment option.
May 2, 2019
0
1
A new liquid biopsy test could detect microsatellite instability (MSI) and tumor mutational burden (TMB), indicating that it could help determine which patients are likely to respond to immune checkpoint inhibitors, according ...
Sep 11, 2019
0
4
A study at The University of Texas MD Anderson Cancer Center discovered a novel therapeutic vulnerability for patients who have tumors caused by a genetic misfire in the DNA mismatch repair (MMR) pathway, a system for repairing ...
Feb 27, 2020
0
2
